BIOAFFINITY TECHNOLOGIES INC C/WTS 07/09/2027 (TO PUR COM) | 8-K: FY2026 Q2 Revenue: USD 1.511 M

Revenue: As of FY2026 Q2, the actual value is USD 1.511 M.

EPS: As of FY2026 Q2, the actual value is USD -0.64.

EBIT: As of FY2026 Q2, the actual value is USD -3.327 M.

Revenue

Revenue for the quarter ended June 30, 2026, was $1.5 million, a 19% increase from $1.3 million reported for the same period in 2025, primarily due to increased sales of CyPath Lung. CyPath Lung testing revenue for the first six months of 2026 increased 159% to approximately $835,000, compared with approximately $323,000 for the first six months of 2025. Net revenue for the six months ended June 30, 2026, was $2,862,106, compared to $3,123,080 for the same period in 2025.

Operating Expenses

Total operating expenses for the second quarter of 2026 were $4.8 million, up from $3.8 million in the second quarter of 2025. Direct costs and expenses were $1.1 million in Q2 2026, compared to $1 million in Q2 2025, reflecting higher CyPath Lung test volume. Research and development expenses increased 16% year-over-year to $362,000 in Q2 2026, driven by laboratory supply purchases and lab relocation costs. Clinical development expenses rose to $476,000 in Q2 2026 from $129,000 in Q2 2025, due to costs associated with initiating a longitudinal clinical study. Selling, general and administrative expenses were $2.9 million for Q2 2026, up from $2.2 million in Q2 2025, mainly due to higher employee compensation. Total operating expenses for the six months ended June 30, 2026, were $9,813,946, compared to $8,265,779 for the same period in 2025.

Net Loss

Net loss for the quarter ended June 30, 2026, was - $3.4 million, compared with a net loss of - $4.1 million for the second quarter of 2025. Loss from operations for the six months ended June 30, 2026, was - $6,951,840, compared to - $5,142,699 for the same period in 2025. Net loss for the six months ended June 30, 2026, was - $6,996,692, compared to - $6,721,204 for the same period in 2025.

Cash and Cash Equivalents

Cash and cash equivalents as of June 30, 2026, were $2.4 million, compared with $6.4 million as of December 31, 2025.

Operational Metrics (CyPath Lung)

CyPath® Lung diagnostic test volume increased 216% year over year in Q2 2026. The company delivered 1,097 CyPath Lung test reports during the first six months of 2026, compared with 390 during the same period of 2025. The number of physician offices and clinics ordering CyPath Lung increased 122% during Q2 2026 compared to Q2 2025. Existing clients as of June 30, 2025, increased their CyPath Lung orders by 71% year over year during the first six months of 2026.

Other Financial Activities

In June 2026, bioAffinity Technologies, Inc. completed a public offering that generated approximately $3.2 million in gross proceeds to support commercialization, clinical development, and general corporate purposes.

Outlook / Guidance

For the second half of 2026, bioAffinity Technologies, Inc. prioritizes expanding physician adoption, increasing utilization among existing customers, and introducing CyPath Lung to new healthcare systems and specialty practices. The company is also advancing its pipeline with positive research and development results in precision diagnostics and a therapeutic for skin cancers. This balanced approach is expected to create lasting value for patients, healthcare providers, and shareholders.